Flash Finance

GlaxoSmithKline Pharmaceuticals LimitedGLAXOCorporate

Healthcare Drug Manufacturers - General Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹2,566.10
MCap ₹43,471 Cr · P/E 41.0
GlaxoSmithKline Pharmaceuticals Limited — Stock analysis & AI research GlaxoSmithKline Pharmaceuticals Limited — Seasonality — best & worst months GlaxoSmithKline Pharmaceuticals Limited — Technical indicators & charts GlaxoSmithKline Pharmaceuticals Limited — Technical setup — score, trend, support & resistance GlaxoSmithKline Pharmaceuticals Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks Cheaper Than Their Industry📋 Low Debt Stocks ⚖️ vs Abbott India⚖️ vs Pfizer 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹924 Cr
Sales · Jun 2026
+14.9% YoY
₹293 Cr
Operating Profit · Jun 2026
+16.9% YoY
31.7%
OPM % · Jun 2026
+1.6% YoY
₹253 Cr
Net Profit · Jun 2026
+23.8% YoY
—
EPS · Jun 2026

📝 GlaxoSmithKline Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹924 crore for the quarter ended June 2026 (Q1 FY27), up 14.9% from ₹805 crore in the same quarter last year, and down 6.5% sequentially over the March 2026 quarter.

Net profit rose 23.8% year-on-year to ₹253 crore, from ₹205 crore.

Operating profit stood at ₹293 crore — an operating margin (OPM) of 31.7%, compared with 31.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, GlaxoSmithKline Pharmaceuticals Limited posted revenue of ₹3,790 crore, a growth of 1.8% over FY25, with a net profit of ₹1,012 crore (up 10.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,910 crore with a net profit of ₹1,061 crore.

Valuation snapshot

At the current price of ₹2,566.10, GLAXO has a market capitalisation of ₹43,471 crore and a trailing P/E of about 41.0.

Within the Drug Manufacturers - General industry, it is the largest of the 5 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 75.00%, foreign institutional investors (FIIs) 4.75%, domestic institutional investors (DIIs) 8.48%, public shareholders 11.77% of GlaxoSmithKline Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹43,471 Cr
Current Price ?
₹2,566.1
P/E ?
40.99below ind
Industry P/E ?
62.30
P/B ?
19.40
P/S ?
11.12
P/FCF ?
52.38
Enterprise Value ?
₹43,504 Cr
EV/EBITDA ?
32.41
PEG ?
2.56
Earnings Yield ?
2.9%
Dividend Yield ?
2.24%
Profitability & Returns
Sales (TTM) ?
₹3,910 Cr
OPM ?
34.3%
Profit after tax (TTM) ?
₹1,061 Cr
EPS (TTM) ?
₹62.60
ROCE ?
61.0%
ROE ?
47.3%
ROA ?
24.8%
Growth
Sales — latest qtr ?
₹924 Cr
PAT — latest qtr ?
₹253 Cr
YoY qtr sales growth ?
14.9%
YoY qtr profit growth ?
23.8%
Sales growth (3y) ?
6%
Sales growth (5y) ?
5%
Profit growth (3y) ?
16%
Profit growth (5y) ?
14%
Financial Health
Debt ?
₹33 Cr
Debt to Equity ?
0.01
Interest Coverage ?
395.4
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.00%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
4.5%
Return 6 months ?
4.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 7997827389538059118111,0009469668059741,023989924 +14.9% -6.5%
Operating Profit 228167141287218255229319290331251335368347293 +16.9% -15.5%
Other Income 242837282830363235394431323662 +40.8% +71.2%
Interest 010001000101111 +131.0% -3.0%
Depreciation 161716181718161719151617201316 +2.1% +21.8%
Profit Before Tax 22418717929765269248339306355279351378369338 +21.3% -8.4%
Net Profit 16413113121645193182249229260205255277275253 +23.8% -7.9%
EPS 9.687.767.7112.722.6911.4010.7214.6813.4915.3612.0815.0616.3616.23— — —
OPM % 28.5% 21.3% 19.1% 30.1% 27.0% 28.0% 28.3% 31.9% 30.7% 34.2% 31.2% 34.4% 35.9% 35.1% 31.7% +1.6% -9.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹3,723 Cr ₹3,790 Cr ₹3,910 Cr +1.8%
Operating Profit ₹1,169 Cr ₹1,300 Cr ₹1,342 Cr +11.2%
OPM % 31.40% 34.30% 34.34% +9.2%
NPM % 24.68% 26.70% 27.13% +8.2%
Other Income ₹143 Cr ₹143 Cr ₹161 Cr +0.2%
Depreciation ₹67 Cr ₹66 Cr ₹67 Cr -0.8%
Interest ₹1 Cr ₹3 Cr ₹4 Cr +138.2%
EBIT ₹1,102 Cr ₹1,234 Cr ₹1,276 Cr +11.9%
PBT ₹1,248 Cr ₹1,376 Cr ₹1,436 Cr +10.2%
Tax ₹329 Cr ₹270 Cr ₹281 Cr -18.0%
Net Profit ₹919 Cr ₹1,012 Cr ₹1,061 Cr +10.1%
EPS ₹54.25 ₹59.73 ₹47.65 +10.1%
Material Cost ₹1,316 Cr ₹981 Cr ₹1,066 Cr -25.5%
Employee Cost ₹580 Cr ₹442 Cr ₹449 Cr -23.7%
Extraordinary Items ₹5 Cr ₹3 Cr ₹3 Cr -43.7%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 169169169169 +0.0%
Reserves 1,5841,6151,7802,072 +16.4%
Borrowings 16191033 +230.0%
Other Liabilities 1,5591,7452,1422,000 -6.6%
Total Liabilities 3,3283,5484,1014,275 +4.2%
Fixed Assets 330321284281 -1.1%
CWIP 20141433 +135.7%
Investments 5438381,1431,416 +23.9%
Other Assets 2,4352,3752,6602,545 -4.3%
Total Assets 3,3283,5484,1014,275 +4.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 4885791,280881 -31.2%
Cash from Investing Activity 80515-37385 +1140.5%
Cash from Financing Activity -1,544-562-769-737 +4.2%
Net Cash Flow -25132474530 +11.8%
Free Cash Flow 4555701,263830 -34.3%
CFO/OP 94%92%116%92% -20.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 22242926 -10.3%
Inventory Days 128146124119 -4.0%
Days Payable 122174188152 -19.1%
Cash Conversion Cycle 27-4-36-7 +80.6%
Working Capital Days -59-66-102-92 +9.8%
ROCE % 36%51%63%61% -3.2%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 75.00%75.00%75.00%75.00%75.00% +0.0%
FIIs 4.89%4.79%4.63%4.62%4.75% +2.8%
DIIs 7.71%7.75%7.70%7.68%8.48% +10.4%
Government 0.00%0.00%0.00%0.00%— —
Public 12.41%12.45%12.67%12.69%11.77% -7.2%
No. of Shareholders 1,23,6291,22,9041,22,4601,21,7631,19,337 -2.0%

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 GLAXO GlaxoSmithKline Pharmaceuticals ₹2,818.90 47,754 44.7 3,955 1,068 40.8% 27.0% 1.9% 11.6% 16.6% 15.7%
2 RUBICON RUBICON RESEARCH ₹1,839.40 30,367 103.7 1,936 288 23.3% 14.9% — — 51.8% 97.2%
3 PFIZER Pfizer ₹4,055.00 18,551 25.2 2,569 735 36.7% 28.6% 10.4% -5.8% 8.3% 6.2%
4 SAIPARENT Sai Parenterals ₹498.00 2,200 — — — — — — — 435.1% 458.0%
5 SYMBIOTEC Symbiotec Pharmalab ₹1,107.00 — — — — — — — — 7.5% -53.1%
❓ Frequently asked questions
What was GlaxoSmithKline Pharmaceuticals Limited's revenue in Q1 FY27?
GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹924 crore for the quarter ended June 2026 (Q1 FY27), up 14.9% from ₹805 crore in the same quarter last year, and down 6.5% sequentially over the March 2026 quarter.
What was GlaxoSmithKline Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 23.8% year-on-year to ₹253 crore, from ₹205 crore.
What is GLAXO's market capitalisation and P/E ratio?
At the current price of ₹2,566.10, GLAXO has a market capitalisation of ₹43,471 crore and a trailing P/E of about 41.0.
Who owns GlaxoSmithKline Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 75.00%, foreign institutional investors (FIIs) 4.75%, domestic institutional investors (DIIs) 8.48%, public shareholders 11.77% of GlaxoSmithKline Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI